Conventional wisdom says HIV is a mature market: the science is settled, the drugs work, the growth is elsewhere. What we're seeing says otherwise. Right now, more than twenty distinct antiretrovirals are accelerating at once — a denser cluster than any single type of cancer produces. When a "solved" disease generates this much fresh activity simultaneously, something commercial is happening. It's worth naming precisely.
From the Knitify Pharma Demand Radar — our running read on where pharmaceutical demand is heading. We publish the observations; the method behind them stays in-house.
It's not discovery. It's a formulation war.
Here's the tell: the targets are all known. Nobody in this cluster is chasing a new mechanism. What's moving is everything around the molecules — long-acting injectables, tenofovir-sparing pairs, single-tablet regimens, and PrEP. The backbone of the market's dominant regimens is re-accelerating hard, and so are older agents that should be fading — the classic signature of fixed-dose-combination and new-formulation work. This is a war fought over a fixed toolkit of drugs.
The clearest confirmation comes from the one molecule climbing from a near-standing start: a next-generation NNRTI whose rise isn't noise about an old drug but the paper trail of a live program. That program is real — the FDA approved it, paired with islatravir, as IDVYNSO: a once-daily, tenofovir-free two-drug regimen shown non-inferior to the three-drug standard of care. [1] We caught the chemistry of a launch. That pattern — a settled target, a re-energized molecule, a new way to combine or deliver it — repeats across the cluster.
A fixed toolkit, and why it stays fixed
The virus's life cycle offers only a short list of choke points, and medicine has occupied each one. Reverse-transcriptase inhibitors — the nucleoside analogs (NRTIs) and the non-nucleoside class (NNRTIs) — block the step where HIV copies its RNA into DNA. Protease inhibitors jam the enzyme that cuts viral proteins into working parts. Integrase inhibitors stop the viral DNA from integrating into the host genome. The newest arrival, the capsid inhibitors, targets the protein shell the virus needs to assemble and uncoat. A handful of families, one virus — and every drug in the accelerating cluster belongs to one of them.
No single one of these drugs is used alone, and the reason is written into the biology of the virus. HIV replicates fast and copies itself sloppily, so the population inside one patient is really a swarm of variants. Hand that swarm a single drug and a resistant variant already present is simply selected for; within weeks the drug fails. The answer, worked out in the 1990s and still the governing principle, is combination therapy — the triple therapy once branded HAART. Hit the virus at two or three points at once, from different mechanism classes, and the odds that any variant already resists all of them collapse toward zero.
That single rule makes HIV a combination market by nature. A new molecule is not a standalone product but a component that must pair cleanly with others, so creativity flows into pairings, backbones, and boosters rather than fresh targets. Match an inhibitor with the right partner in one daily tablet and the combination itself becomes the invention — which is why the record fills with combinations, not compounds.
The real frontier is how often you dose
To see why this is a formulation war and not a discovery race, look at what's actually changing. The mechanism classes are decades established; what's moving is the delivery. The field has walked from a daily pill, to a long-acting injectable given every two months (cabotegravir with rilpivirine), toward dosing measured in months rather than days. [2]
The most striking step is prevention. In 2025 the FDA approved a twice-yearly injectable, lenacapavir, for HIV prevention, and the World Health Organization recommended it — a single molecule that turns protection from a daily discipline into two appointments a year. [3] Each of these advances is a fresh wave of formulation and combination patents on a known set of molecules — long-acting depots, co-formulations, new salts, particle engineering. The chemistry doesn't have to be novel to be in demand. It has to be delivered a new way.
The science of making a drug last
Turning a daily pill into a twice-a-year injection is one of the harder problems in pharmaceutical science, and it is where much of this cluster's chemistry lives. A swallowed pill clears within a day; to make a molecule persist for months you have to build a reservoir inside the body. The dominant approach is the long-acting depot — the drug formulated as a suspension of tiny solid particles, nanocrystals or microcrystals, injected into muscle or under the skin, where they dissolve gradually and feed a controlled trickle into the blood for months.
None of that comes for free. The molecule has to cooperate: potent enough that a tolerable injection volume carries a full dose, yet insoluble enough to dissolve slowly instead of dumping all at once. Particle size, crystal form, salt, and surface chemistry all have to be held to tight tolerances, because the particle is the release mechanism — shift its size distribution and you shift the dosing interval. And because an injected depot cannot be recalled, a molecule that lingers for months at low levels risks coaching resistance as it clears. All of it is why new salts, polymorphs, and particle-engineered formulations — not novel compounds — are the real invention here, and why a manufacturer who solves it holds a moat measured in know-how, not in a single patent.
Prevention, access, and the generic backbone
The move from treatment to prevention changes the stakes entirely. Pre-exposure prophylaxis — PrEP — means giving antiretrovirals to people who do not have HIV so they never acquire it. As a daily pill, PrEP works, but it asks near-perfect adherence from otherwise healthy people, which is exactly where real-world protection frays. A twice-yearly injection reframes the problem: protection becomes two clinic visits a year rather than a discipline sustained every morning. For public health, that is potentially the difference between a tool and a turning point: prevention that does not lean on daily behavior can bend an epidemic's curve.
It also raises the ceiling on volume. Effective, convenient prevention addresses a far larger at-risk population than treatment does, much of it where the epidemic is heaviest and health budgets thinnest. That is the seam where the other half of the antiretroviral market lives — the generic, fixed-dose-combination backbone that supplies global-health programs at scale. Most people on HIV therapy worldwide are taking robust, off-patent combinations made in enormous quantity at low margin, not the newest branded regimen. And today's innovator format is tomorrow's generic, so when prevention shifts toward injectables, who can produce a sterile long-acting suspension at scale becomes a supply question, not just a science one.
Who this is a forecast for
If you make or source antiretroviral APIs, this cluster is a demand forecast. Accelerating demand tends to run 12 to 24 months ahead of procurement, so it points at where combination and long-acting programs will need supply before the tonnage ever shows up in a purchase order. But the signal reads differently depending on where you sit in the chain.
For API makers, a molecule whose combinations are multiplying is one whose volume is about to climb, often before the order lands. For CDMOs and formulation specialists, the value has moved downstream: the scarce capability is now sterile injectable manufacturing, particle engineering, and long-acting depot fill-finish — the exact skills a format shift demands. For generic manufacturers, the same read previews which off-patent backbones and fixed-dose combinations will anchor the next global-health tenders. And for global-health buyers, an early view of where formats are heading is a planning tool for the volumes, budgets, and cold-chain they will fund.
The molecules whose delivery format is changing are the ones where a contract manufacturer with the right formulation capability has something specific to sell, to a nameable set of buyers. That's the move: not just what is heating up, but who to call. We keep the ranked list and the buyer roster for subscribers — but the shape of this one is unmistakable.
What the signal can't tell you
A demand read is a lead indicator, not a guarantee, and it comes with honest caveats. The patent record is a lagging shadow of live research: filings become visible long after the work that produced them, so what surfaces now reflects decisions taken a year or more ago. That lag is what makes the signal useful as a forecast — but it also means the record shows direction, not certainty, and a program can stall in the gap between the filing and the market.
The clinical and commercial tradeoffs are real too. Long-acting convenience competes with cost and complexity: an injection every few months needs a clinic, a cold chain, and trained staff, which is not automatically cheaper or simpler than a pill in every setting. Adherence gains have to be weighed against delivery burden, and the calculus looks very different in a well-resourced clinic than in an overstretched public program.
Finally, HIV medicine is inseparable from access and pricing politics. Voluntary licensing, tiered pricing, generic competition, and donor funding decide how far and how fast these advances reach patients, and can accelerate or throttle real demand independent of the science. A patent surge tells you where the chemistry is heading; it does not tell you who will be allowed to make it, at what price, or who will pay. Reading the science is the first step; reading the commerce that forms around it is the harder one — and it is the one that decides where the tonnage actually goes.
Editorial commentary from the Knitify Pharma Demand Radar. Not investment, legal, regulatory, or medical advice.